Drugs / Visugromab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04725474 | Dec 2020 → Apr 2028 expected | cancer | CatalYm GmbH | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07219459 | Mar 2026 → Sep 2029 expected | hepatocellular carcinoma | CatalYm GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT07246863 | Oct 2025 → Oct 2029 expected | non-small cell lung carcinoma | CatalYm GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT07098988 | Aug 2025 → Mar 2029 expected | non-small cell lung carcinoma | CatalYm GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT06059547 | Sep 2023 → Oct 2025 overdue | urinary bladder cancer | CatalYm GmbH | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07112196 Comparator | Apr 2026 → Dec 2029 expected | — | CatalYm GmbH | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | visugromab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04725474 ↗ |
| Known as | CTL-002 | “IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy” NCT04725474 ↗ |
| Action | Inhibit | “Visugromab, a neutralizing anti-GDF-15 antibody” PMID 42426863 ↗ Jul 2026 |
| Modality | Monoclonal antibody | “visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15)” NCT04725474 ↗ |
| Route | Intravenous | “Intravenous (IV) Administration of CTL-002” NCT04725474 ↗ |
| Target | GDF15 | “a monoclonal antibody neutralizing GDF-15” NCT04725474 ↗ |